In Brief: FDA's Psychopharmacologic Drugs Advisory Committee
FDA's Psychopharmacologic Drugs Advisory Committee: Will meet Feb. 6 to discuss Abbott Lab's NDA (20-320) for Depakote (divalproex sodium) tablets for "use in the treatment of manic episodes associated with bipolar disorder." The meeting will begin at 8:30 a.m. in Conference Rooms D and E of FDA's Parklawn Building, Rockville, Md...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth